You are here

  • Home
  • Archive
  • Volume 9, Issue 6
  • Δ133p53α enhances metabolic and cellular fitness of TCR-engineered T cells and promotes superior antitumor immunity

Article info

Article menu
XML
Immune cell therapies and immune cell engineering
Original research
Δ133p53α enhances metabolic and cellular fitness of TCR-engineered T cells and promotes superior antitumor immunity

Authors

  • Kevin Jan Legscha Department of Hematology, Oncology and Pneumology, University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany PubMed articlesGoogle scholar articles
  • Edite Antunes Ferreira Department of Hematology, Oncology and Pneumology, University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany PubMed articlesGoogle scholar articles
  • Antonios Chamoun Department of Hematology, Oncology and Pneumology, University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany PubMed articlesGoogle scholar articles
  • Alexander Lang Department of Hematology, Oncology and Pneumology, University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany PubMed articlesGoogle scholar articles
  • Mohamed Hemaid Sayed Awwad Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany PubMed articlesGoogle scholar articles
  • Gigi Nu Hoang Quy Ton Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany PubMed articlesGoogle scholar articles
  • Danuta Galetzka Department of Radiation Oncology and Radiotherapy, University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany PubMed articlesGoogle scholar articles
  • Borhane Guezguez Department of Hematology, Oncology and Pneumology, University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany German Cancer Consortium (DKTK), Partner Site, Mainz, Germany PubMed articlesGoogle scholar articles
  • Michael Hundemer Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany PubMed articlesGoogle scholar articles
  • Jean-Christophe Bourdon School of Medicine, University of Dundee, Dundee, UK PubMed articlesGoogle scholar articles
  • Markus Munder Department of Hematology, Oncology and Pneumology, University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany Research Center for Immunotherapy (FZI), University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany PubMed articlesGoogle scholar articles
  • Matthias Theobald Department of Hematology, Oncology and Pneumology, University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany German Cancer Consortium (DKTK), Partner Site, Mainz, Germany Research Center for Immunotherapy (FZI), University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany PubMed articlesGoogle scholar articles
  • Hakim Echchannaoui Department of Hematology, Oncology and Pneumology, University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany German Cancer Consortium (DKTK), Partner Site, Mainz, Germany PubMed articlesGoogle scholar articles

Citation

Legscha KJ, Antunes Ferreira E, Chamoun A, et al
Δ133p53α enhances metabolic and cellular fitness of TCR-engineered T cells and promotes superior antitumor immunity
Journal for ImmunoTherapy of Cancer 2021;9:e001846. doi: 10.1136/jitc-2020-001846
Online issue publication 
February 24, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.